Johnson & Johnson (NYSE:JNJ) Issues FY 2025 Earnings Guidance

Key Points

• Johnson & Johnson has provided updated earnings guidance for FY 2025, expecting earnings per share between $10.800 and $10.900, along with revenue guidance of $93.5 billion to $93.9 billion.
• Major analysts upgraded their ratings on JNJ, with Goldman Sachs raising its price target to $212.00 and Weiss Ratings upgrading to a "buy" rating.
• The company announced a quarterly dividend of $1.30 per share, representing an annualized yield of 2.7%, to be paid on December 9th, 2023.

Johnson & Johnson (NYSE:JNJ - Get Free Report) updated its FY 2025 earnings guidance on Tuesday. The company provided earnings per share guidance of 10.800-10.900 for the period, compared to the consensus earnings per share estimate of 10.860. The company issued revenue guidance of $93.5 billion-$93.9 billion, compared to the consensus revenue estimate of $93.4 billion.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on JNJ shares. Royal Bank Of Canada restated an "outperform" rating and issued a $209.00 target price on shares of Johnson & Johnson in a report on Friday. Weiss Ratings raised shares of Johnson & Johnson from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Wednesday, October 8th. The Goldman Sachs Group lifted their price target on shares of Johnson & Johnson from $186.00 to $212.00 and gave the stock a "buy" rating in a research note on Thursday, October 9th. JPMorgan Chase & Co. lifted their price target on shares of Johnson & Johnson from $185.00 to $200.00 and gave the stock a "neutral" rating in a research note on Tuesday, September 16th. Finally, Barclays increased their target price on shares of Johnson & Johnson from $165.00 to $176.00 and gave the stock an "equal weight" rating in a report on Thursday, July 17th. Two analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $192.94.

Johnson & Johnson Price Performance

NYSE JNJ opened at $190.88 on Tuesday. The stock's 50-day moving average price is $178.88 and its two-hundred day moving average price is $163.97. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The company has a market cap of $459.71 billion, a PE ratio of 20.42, a PEG ratio of 2.40 and a beta of 0.40. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $192.10.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. The business had revenue of $24.02 billion during the quarter. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. On average, analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be paid a $1.30 dividend. The ex-dividend date is Tuesday, November 25th. This represents a $5.20 annualized dividend and a dividend yield of 2.7%. Johnson & Johnson's dividend payout ratio (DPR) is presently 55.61%.

Insider Activity

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the firm's stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president directly owned 178,013 shares of the company's stock, valued at $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.16% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Brighton Jones LLC increased its position in Johnson & Johnson by 13.9% in the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock worth $7,502,000 after purchasing an additional 6,332 shares during the period. Sivia Capital Partners LLC boosted its holdings in shares of Johnson & Johnson by 13.4% in the second quarter. Sivia Capital Partners LLC now owns 5,863 shares of the company's stock valued at $896,000 after buying an additional 692 shares during the period. Strategic Investment Advisors MI lifted its stake in Johnson & Johnson by 9.8% in the 2nd quarter. Strategic Investment Advisors MI now owns 3,667 shares of the company's stock valued at $560,000 after acquiring an additional 327 shares in the last quarter. Garden State Investment Advisory Services LLC lifted its stake in Johnson & Johnson by 17.7% in the 2nd quarter. Garden State Investment Advisory Services LLC now owns 2,823 shares of the company's stock valued at $432,000 after acquiring an additional 424 shares in the last quarter. Finally, SkyView Investment Advisors LLC lifted its stake in Johnson & Johnson by 10.2% in the 2nd quarter. SkyView Investment Advisors LLC now owns 2,530 shares of the company's stock valued at $386,000 after acquiring an additional 235 shares in the last quarter. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.